🇺🇸 FDA
Pipeline program

ARCT-810

ARCT-810-04

Phase 2 mab active

Quick answer

ARCT-810 for OTC Deficiency is a Phase 2 program (mab) at Arcturus Therapeutics Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcturus Therapeutics Holdings
Indication
OTC Deficiency
Phase
Phase 2
Modality
mab
Status
active

Clinical trials